Literature DB >> 17603638

New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003.

Michael Crooke1.   

Abstract

Year:  2007        PMID： 17603638      PMCID： PMC1904419     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN： 0159-8090


× No keyword cloud information.
  42 in total

1.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

2.  Quality and equity in cardiovascular health in New Zealand: the need for agreed achievable standards of care, cohesive planning, and action.

Authors:  Norman Sharpe; Gerard Wilkins
Journal:  N Z Med J       Date:  2004-07-09

3.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

4.  National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.

Authors:  Andrew Tonkin; Philip Barter; James Best; Andrew Boyden; John Furler; Ken Hossack; David Sullivan; Peter Thompson; Margarite Vale; Catherine Cooper; Malia Robinson; Eleanor Clune
Journal:  Heart Lung Circ       Date:  2005-12       Impact factor: 2.975

5.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

Authors:  James M McKenney; Michael H Davidson; Terry A Jacobson; John R Guyton
Journal:  Am J Cardiol       Date:  2006-02-28       Impact factor: 2.778

6.  New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003.

Authors:  Michael Crooke
Journal:  Clin Biochem Rev       Date:  2007-02

7.  1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand.

Authors: 
Journal:  N Z Med J       Date:  1996-06-28

8.  Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first 18,000 patients (PREDICT CVD-1).

Authors:  Lot Bannink; Susan Wells; Joanna Broad; Tania Riddell; Rod Jackson
Journal:  N Z Med J       Date:  2006-11-17

9.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

10.  Cardiovascular disease risk profiles.

Authors:  K M Anderson; P M Odell; P W Wilson; W B Kannel
Journal:  Am Heart J       Date:  1991-01       Impact factor: 4.749
View more
  6 in total

1.  New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003.

Authors:  Michael Crooke
Journal:  Clin Biochem Rev       Date:  2007-02

2.  From evidence to practice: consensus in cardiovascular risk assessment and diabetes.

Authors:  Michael Crooke
Journal:  Clin Biochem Rev       Date:  2009-11

3.  Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative.

Authors:  Sheldon W Tobe; James A Stone; Melissa Brouwers; Onil Bhattacharyya; Kimberly M Walker; Martin Dawes; Jacques Genest; Steven Grover; Gordon Gubitz; David Lau; Andrew Pipe; Peter Selby; Mark S Tremblay; Darren E R Warburton; Richard Ward; Vincent Woo; Lawrence A Leiter; Peter P Liu
Journal:  CMAJ       Date:  2011-09-12       Impact factor: 8.262

4.  Development and Validation of a Novel Tool for Assessing the Environmental Impact of 3D Printing Technologies: A Pharmaceutical Perspective.

Authors:  Souha H Youssef; Sadikalmahdi Abdella; Sanjay Garg
Journal:  Pharmaceutics       Date:  2022-04-25       Impact factor: 6.525

5.  Decision tree analysis of traditional risk factors of carotid atherosclerosis and a cutpoint-based prevention strategy.

Authors:  Guangming Qin; Laisheng Luo; Lihong Lv; Yufei Xiao; Jiangfeng Tu; Lisha Tao; Jiaqi Wu; Xiaoxiao Tang; Wensheng Pan
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

6.  Roles of triglyceride and phosphate in atherosclerosis of diabetic hemodialysis patients.

Authors:  Mohammad Rezapour; Elnaz Payani; Masoumeh Taran; Ali Rajabzadeh Ghatari; Morteza Khavanin Zadeh
Journal:  Med J Islam Repub Iran       Date:  2017-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.